-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, A6hwMvnrqkNHLV1q1/0MzsECIs4tm6CCA9KTCtXLAKGBWIyUeebquiHpNfsP7NWG GOIRFPcgfAL/XEpm7E48Sw== 0000950123-10-012282.txt : 20100212 0000950123-10-012282.hdr.sgml : 20100212 20100212161209 ACCESSION NUMBER: 0000950123-10-012282 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20100212 DATE AS OF CHANGE: 20100212 GROUP MEMBERS: BOULDER VENTURES IV, L.P. GROUP MEMBERS: BV PARTNERS IV, L.L.C. GROUP MEMBERS: JOSH E. FIDLER GROUP MEMBERS: KYLE LEFKOFF GROUP MEMBERS: LAWRENCE M. MACKS GROUP MEMBERS: PETER ROSHKO SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: ARCA biopharma, Inc. CENTRAL INDEX KEY: 0000907654 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 363855489 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-51477 FILM NUMBER: 10599447 BUSINESS ADDRESS: STREET 1: 8001 ARISTA PLACE STREET 2: SUITE 200 CITY: BROOMFIELD STATE: CO ZIP: 80021 BUSINESS PHONE: 720-940-2200 MAIL ADDRESS: STREET 1: 8001 ARISTA PLACE STREET 2: SUITE 200 CITY: BROOMFIELD STATE: CO ZIP: 80021 FORMER COMPANY: FORMER CONFORMED NAME: NUVELO INC DATE OF NAME CHANGE: 20030203 FORMER COMPANY: FORMER CONFORMED NAME: HYSEQ INC DATE OF NAME CHANGE: 19970610 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BOULDER VENTURES IV ANNEX LP CENTRAL INDEX KEY: 0001165197 IRS NUMBER: 522289816 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: 1900 NINTH STREET, SUITE 200 CITY: BOULDER STATE: CO ZIP: 80302 BUSINESS PHONE: 3034446950 MAIL ADDRESS: STREET 1: 1900 NINTH STREET, SUITE 200 CITY: BOULDER STATE: CO ZIP: 80302 SC 13G/A 1 d71011sc13gza.htm SC 13G/A sc13gza

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934
(Amendment No. 1)*

ARCA BIOPHARMA, INC.
(Name of Issuer)
COMMON STOCK
(Title of Class of Securities)
00211Y 10 0
(CUSIP Number)
DECEMBER 31, 2009
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     o Rule 13d-1(b)

     þ Rule 13d-1(c)

     o Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 
 

 

                       
CUSIP No.
  
00211Y 10 0 
 13G Page  
2
   of  
12
  Pages

 

           
1.   NAMES OF REPORTING PERSONS
Boulder Ventures IV (Annex), L.P.
     
     
2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
  (a)   o
  (b)   þ(1)
     
3.   SEC USE ONLY
   
   
     
4.   CITIZENSHIP OR PLACE OF ORGANIZATION
   
  Delaware, United States of America
       
  5.   SOLE VOTING POWER
     
NUMBER OF   0 shares
       
SHARES 6.   SHARED VOTING POWER
BENEFICIALLY    
OWNED BY   0 shares
       
EACH 7.   SOLE DISPOSITIVE POWER
REPORTING    
PERSON   0 shares
       
WITH: 8.   SHARED DISPOSITIVE POWER
     
    0 shares
     
9.   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
   
  0 shares
     
10.   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
   
  o
     
11.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
   
  0.0%
     
12.   TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
   
  PN
(1) This Schedule 13G is filed by Boulder Ventures IV (Annex), L.P. (“BV IV Annex”), Boulder Ventures IV, L.P. (“BV IV LP”), BV Partners IV, L.L.C. (“BV PARTNERS IV LLC”), Josh E. Fidler (“Fidler”), Kyle Lefkoff (“Lefkoff”), Lawrence M. Macks (“Macks”) and Peter Roshko (“Roshko”) (collectively, the “Fund Entities”). The Fund Entities expressly disclaim status as a “group” for purposes of this Schedule 13G. BV PARTNERS IV LLC serves as the general partner of BV IV Annex and BV IV LP, and owns no securities of the Issuer directly. Fidler, Lefkoff, Macks and Roshko are Managing Members of BV PARTNERS IV LLC and share voting and dispositive power over the shares held by BV IV Annex and BV IV LP. The information with respect to the ownership of the Common Stock by the Fund Entities filing this Amendment No. 1 to the statement on Schedule 13G is provided as of December 31, 2009.

 

                       
CUSIP No.
  
00211Y 10 0 
 13G Page  
3
   of  
12
  Pages

 

           
1.   NAMES OF REPORTING PERSONS
Boulder Ventures IV, L.P.
     
     
2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
  (a)   o
  (b)   þ(1)
     
3.   SEC USE ONLY
   
   
     
4.   CITIZENSHIP OR PLACE OF ORGANIZATION
   
  Delaware, United States of America
       
  5.   SOLE VOTING POWER
     
NUMBER OF   0 shares
       
SHARES 6.   SHARED VOTING POWER
BENEFICIALLY    
OWNED BY   0 shares
       
EACH 7.   SOLE DISPOSITIVE POWER
REPORTING    
PERSON   0 shares
       
WITH: 8.   SHARED DISPOSITIVE POWER
     
    0 shares
     
9.   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
   
  0 shares
     
10.   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
   
  o
     
11.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
   
  0.0%
     
12.   TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
   
  PN
(1) This Schedule 13G is filed by Boulder Ventures IV (Annex), L.P. (“BV IV Annex”), Boulder Ventures IV, L.P. (“BV IV LP”), BV Partners IV, L.L.C. (“BV PARTNERS IV LLC”), Josh E. Fidler (“Fidler”), Kyle Lefkoff (“Lefkoff”), Lawrence M. Macks (“Macks”) and Peter Roshko (“Roshko”) (collectively, the “Fund Entities”). The Fund Entities expressly disclaim status as a “group” for purposes of this Schedule 13G. BV PARTNERS IV LLC serves as the general partner of BV IV Annex and BV IV LP, and owns no securities of the Issuer directly. Fidler, Lefkoff, Macks and Roshko are Managing Members of BV PARTNERS IV LLC and share voting and dispositive power over the shares held by BV IV Annex and BV IV LP. The information with respect to the ownership of the Common Stock by the Fund Entities filing this Amendment No. 1 to the statement on Schedule 13G is provided as of December 31, 2009.

 

                       
CUSIP No.
  
00211Y 10 0 
 13G Page  
4
   of  
12
  Pages

 

           
1.   NAMES OF REPORTING PERSONS
BV Partners IV, L.L.C.
     
     
2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
  (a)   o
  (b)   þ(1)
     
3.   SEC USE ONLY
   
   
     
4.   CITIZENSHIP OR PLACE OF ORGANIZATION
   
  Delaware, United States of America
       
  5.   SOLE VOTING POWER
     
NUMBER OF   0 shares
       
SHARES 6.   SHARED VOTING POWER
BENEFICIALLY    
OWNED BY   0 shares
       
EACH 7.   SOLE DISPOSITIVE POWER
REPORTING    
PERSON   0 shares
       
WITH: 8.   SHARED DISPOSITIVE POWER
     
    0 shares
     
9.   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
   
  0 shares
     
10.   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
   
  o
     
11.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
   
  0.0%
     
12.   TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
   
  PN
(1) This Schedule 13G is filed by Boulder Ventures IV (Annex), L.P. (“BV IV Annex”), Boulder Ventures IV, L.P. (“BV IV LP”), BV Partners IV, L.L.C. (“BV PARTNERS IV LLC”), Josh E. Fidler (“Fidler”), Kyle Lefkoff (“Lefkoff”), Lawrence M. Macks (“Macks”) and Peter Roshko (“Roshko”) (collectively, the “Fund Entities”). The Fund Entities expressly disclaim status as a “group” for purposes of this Schedule 13G. BV PARTNERS IV LLC serves as the general partner of BV IV Annex and BV IV LP, and owns no securities of the Issuer directly. Fidler, Lefkoff, Macks and Roshko are Managing Members of BV PARTNERS IV LLC and share voting and dispositive power over the shares held by BV IV Annex and BV IV LP. The information with respect to the ownership of the Common Stock by the Fund Entities filing this Amendment No. 1 to the statement on Schedule 13G is provided as of December 31, 2009.

 

                       
CUSIP No.
  
00211Y 10 0 
 13G Page  
5
   of  
12
  Pages

 

           
1.   NAMES OF REPORTING PERSONS
Josh E. Fidler
     
     
2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
  (a)   o
  (b)   þ(1)
     
3.   SEC USE ONLY
   
   
     
4.   CITIZENSHIP OR PLACE OF ORGANIZATION
   
  United States of America
       
  5.   SOLE VOTING POWER
     
NUMBER OF   0 shares
       
SHARES 6.   SHARED VOTING POWER
BENEFICIALLY    
OWNED BY   0 shares
       
EACH 7.   SOLE DISPOSITIVE POWER
REPORTING    
PERSON   0 shares
       
WITH: 8.   SHARED DISPOSITIVE POWER
     
    0 shares
     
9.   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
   
  0 shares
     
10.   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
   
  o
     
11.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
   
  0.0%
     
12.   TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
   
  IN
(1) This Schedule 13G is filed by Boulder Ventures IV (Annex), L.P. (“BV IV Annex”), Boulder Ventures IV, L.P. (“BV IV LP”), BV Partners IV, L.L.C. (“BV PARTNERS IV LLC”), Josh E. Fidler (“Fidler”), Kyle Lefkoff (“Lefkoff”), Lawrence M. Macks (“Macks”) and Peter Roshko (“Roshko”) (collectively, the “Fund Entities”). The Fund Entities expressly disclaim status as a “group” for purposes of this Schedule 13G. BV PARTNERS IV LLC serves as the general partner of BV IV Annex and BV IV LP, and owns no securities of the Issuer directly. Fidler, Lefkoff, Macks and Roshko are Managing Members of BV PARTNERS IV LLC and share voting and dispositive power over the shares held by BV IV Annex and BV IV LP. The information with respect to the ownership of the Common Stock by the Fund Entities filing this Amendment No. 1 to the statement on Schedule 13G is provided as of December 31, 2009.

 

                       
CUSIP No.
  
00211Y 10 0 
 13G Page  
6
   of  
12
  Pages

 

           
1.   NAMES OF REPORTING PERSONS
Kyle Lefkoff
     
     
2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
  (a)   o
  (b)   þ(1)
     
3.   SEC USE ONLY
   
   
     
4.   CITIZENSHIP OR PLACE OF ORGANIZATION
   
  United States of America
       
  5.   SOLE VOTING POWER
     
NUMBER OF   0 shares
       
SHARES 6.   SHARED VOTING POWER
BENEFICIALLY    
OWNED BY   0 shares
       
EACH 7.   SOLE DISPOSITIVE POWER
REPORTING    
PERSON   0 shares
       
WITH: 8.   SHARED DISPOSITIVE POWER
     
    0 shares
     
9.   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
   
  0 shares
     
10.   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
   
  o
     
11.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
   
  0.0%
     
12.   TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
   
  IN
(1) This Schedule 13G is filed by Boulder Ventures IV (Annex), L.P. (“BV IV Annex”), Boulder Ventures IV, L.P. (“BV IV LP”), BV Partners IV, L.L.C. (“BV PARTNERS IV LLC”), Josh E. Fidler (“Fidler”), Kyle Lefkoff (“Lefkoff”), Lawrence M. Macks (“Macks”) and Peter Roshko (“Roshko”) (collectively, the “Fund Entities”). The Fund Entities expressly disclaim status as a “group” for purposes of this Schedule 13G. BV PARTNERS IV LLC serves as the general partner of BV IV Annex and BV IV LP, and owns no securities of the Issuer directly. Fidler, Lefkoff, Macks and Roshko are Managing Members of BV PARTNERS IV LLC and share voting and dispositive power over the shares held by BV IV Annex and BV IV LP. The information with respect to the ownership of the Common Stock by the Fund Entities filing this Amendment No. 1 to the statement on Schedule 13G is provided as of December 31, 2009.

 

                       
CUSIP No.
  
00211Y 10 0 
 13G Page  
7
   of  
12
  Pages

 

           
1.   NAMES OF REPORTING PERSONS
Lawrence M. Macks
     
     
2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
  (a)   o
  (b)   þ(1)
     
3.   SEC USE ONLY
   
   
     
4.   CITIZENSHIP OR PLACE OF ORGANIZATION
   
  United States of America
       
  5.   SOLE VOTING POWER
     
NUMBER OF   0 shares
       
SHARES 6.   SHARED VOTING POWER
BENEFICIALLY    
OWNED BY   0 shares
       
EACH 7.   SOLE DISPOSITIVE POWER
REPORTING    
PERSON   0 shares
       
WITH: 8.   SHARED DISPOSITIVE POWER
     
    0 shares
     
9.   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
   
  0 shares
     
10.   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
   
  o
     
11.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
   
  0.0%
     
12.   TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
   
  IN
(1) This Schedule 13G is filed by Boulder Ventures IV (Annex), L.P. (“BV IV Annex”), Boulder Ventures IV, L.P. (“BV IV LP”), BV Partners IV, L.L.C. (“BV PARTNERS IV LLC”), Josh E. Fidler (“Fidler”), Kyle Lefkoff (“Lefkoff”), Lawrence M. Macks (“Macks”) and Peter Roshko (“Roshko”) (collectively, the “Fund Entities”). The Fund Entities expressly disclaim status as a “group” for purposes of this Schedule 13G. BV PARTNERS IV LLC serves as the general partner of BV IV Annex and BV IV LP, and owns no securities of the Issuer directly. Fidler, Lefkoff, Macks and Roshko are Managing Members of BV PARTNERS IV LLC and share voting and dispositive power over the shares held by BV IV Annex and BV IV LP. The information with respect to the ownership of the Common Stock by the Fund Entities filing this Amendment No. 1 to the statement on Schedule 13G is provided as of December 31, 2009.

 

                       
CUSIP No.
  
00211Y 10 0 
 13G Page  
8
   of  
12
  Pages

 

           
1.   NAMES OF REPORTING PERSONS
Peter Roshko
     
     
2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
  (a)   o
  (b)   þ(1)
     
3.   SEC USE ONLY
   
   
     
4.   CITIZENSHIP OR PLACE OF ORGANIZATION
   
  United States of America
       
  5.   SOLE VOTING POWER
     
NUMBER OF   0 shares
       
SHARES 6.   SHARED VOTING POWER
BENEFICIALLY    
OWNED BY   0 shares
       
EACH 7.   SOLE DISPOSITIVE POWER
REPORTING    
PERSON   0 shares
       
WITH: 8.   SHARED DISPOSITIVE POWER
     
    0 shares
     
9.   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
   
  0 shares
     
10.   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
   
  o
     
11.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
   
  0.0%
     
12.   TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
   
  IN
(1) This Schedule 13G is filed by Boulder Ventures IV (Annex), L.P. (“BV IV Annex”), Boulder Ventures IV, L.P. (“BV IV LP”), BV Partners IV, L.L.C. (“BV PARTNERS IV LLC”), Josh E. Fidler (“Fidler”), Kyle Lefkoff (“Lefkoff”), Lawrence M. Macks (“Macks”) and Peter Roshko (“Roshko”) (collectively, the “Fund Entities”). The Fund Entities expressly disclaim status as a “group” for purposes of this Schedule 13G. BV PARTNERS IV LLC serves as the general partner of BV IV Annex and BV IV LP, and owns no securities of the Issuer directly. Fidler, Lefkoff, Macks and Roshko are Managing Members of BV PARTNERS IV LLC and share voting and dispositive power over the shares held by BV IV Annex and BV IV LP. The information with respect to the ownership of the Common Stock by the Fund Entities filing this Amendment No. 1 to the statement on Schedule 13G is provided as of December 31, 2009.

 

Introductory Note: This Amendment No. 1 to the Statement on Schedule 13G is filed on behalf of Boulder Ventures IV (Annex), L.P., a Delaware limited partnership (“BV IV Annex), Boulder Ventures IV, L.P., a Delaware limited partnership (“BV IV LP”), BV Partners IV, L.L.C., a Delaware limited liability company (“BV PARTNERS IV LLC”), Josh E. Fidler (“Fidler”), Kyle Lefkoff (“Lefkoff”), Lawrence M. Macks (“Macks”) and Peter Roshko (“Roshko”), in respect of shares of Common Stock of ARCA biopharma, Inc.
     
Item 1
    
 
    
Item 1(a).
  Name of Issuer: ARCA biopharma, Inc. (ABIO)
 
    
Item 1(b).
  Address of Issuer’s Principal Executive Offices:
 
    
 
  8001 Arista Place, Suite 200
Broomfield Co 80021
 
    
Item 2(a).
  Name of Person(s) Filing:
 
    
 
  Boulder Ventures IV (Annex), L.P. (“BV IV Annex”)
Boulder Ventures IV, L.P. (“BV IV LP”)
BV Partners IV, L.L.C. (“BV PARTNERS IV LLC”)
Josh E. Fidler (“Fidler”)
Kyle Lefkoff (“Lefkoff”)
Lawrence M. Macks (“Macks”)
Peter Roshko (“Roshko”)
 
    
Item 2(b).
  Address of Principal Business Office or, if none, Residence:
 
    
 
  1941 Pearl Street, Suite 300
Boulder, CO 80302
             
Item 2(c).
  Citizenship:        
 
            
 
  Entities:   BV IV Annex   —      Delaware
 
      BV IV LP   —      Delaware
        BV PARTNERS IV LLC    —      Delaware
 
            
 
  Individuals:   Fidler   —      United States of America
 
      Lefkoff   —      United States of America
 
      Macks   —      United States of America
 
      Roshko   —      United States of America
     
Item 2(d).
  Title of Class of Securities: Common Stock
 
    
Item 2(e).
  CUSIP Number: 00211Y 10 0
 
    
Item 3.
  Not applicable.

Page 9 of 12 Pages

 

     
Item 4.
  Ownership
The following information with respect to the ownership of the Common Stock of the Issuer by the persons filing this statement on Amendment No. 1 to the Statement on Schedule 13G is provided as of December 31, 2009:
                                                         
    Shares   Sole   Shared   Sole   Shared        
    Held   Voting   Voting   Dispositive   Dispositive   Beneficial   Percentage
Fund Entities   Directly   Power   Power   Power   Power   Ownership   of Class
Boulder IV Annex (1)
     0       0       0       0       0       0       0.0 %
BV IV LP (1)
     0       0       0       0       0       0       0.0 %
BV PARTNERS IV LLC (1)
     0       0       0       0       0       0       0.0 %
Fidler (1)
     0       0       0       0       0       0       0.0 %
Lefkoff (1)
     0       0       0       0       0       0       0.0 %
Lawrence (1
     0       0       0       0       0       0       0.0 %
Roshko (1)
     0       0       0       0       0       0       0.0 %
 
(1)   BV PARTNERS IV LLC serves as the general partner of BV IV Annex and BV IV LP, and owns no securities of the Issuer directly. Fidler, Lefkoff, Macks and Roshko are Managing Members of PARTNERS IV LLC and share voting and dispositive power over the shares held by BV IV Annex and BV IV LP.
     
Item 5.
  Ownership of 5 Percent or Less of a Class
 
    
 
  If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following þ
 
    
Item 6.
  Ownership of More than 5 Percent on Behalf of Another Person
 
    
 
  Not applicable.
 
    
Item 7.
  Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.
 
    
 
  Not applicable.
 
    
Item 8.
  Identification and Classification of Members of the Group
 
    
 
  Not applicable.
 
    
Item 9.
  Notice of Dissolution of a Group
 
    
 
  Not applicable.
 
    
Item 10.
  Certification
 
    
 
  By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

Page 10 of 12 Pages

 

SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
         
Dated: February 12, 2010
BOULDER VENTURES IV (ANNEX), L.P.
 		    
By:   BV Partners IV, L.L.C.      
Its: General Partner     
 
By:   /s/ Kyle Lefkoff      
  Kyle Lefkoff, Managing Member     
 
BOULDER VENTURES IV, L.P.
 		    
By:   BV Partners IV, LLC      
Its: General Partner     
     
By:   /s/ Kyle Lefkoff      
  Kyle Lefkoff, Managing Member     
 
BV PARTNERS IV, LLC
 		    
By:   /s/ Kyle Lefkoff      
  Kyle Lefkoff, Managing Member     
     
/s/ Josh E. Fidler      
Josh E. Fidler     
     
/s/ Kyle Lefkoff      
Kyle Lefkoff     
     
/s/ Lawrence M. Macks      
Lawrence M. Macks     
     
/s/ Peter Roshko      
Peter Roshko     
Exhibit(s):
A — Joint Filing Statement

Page 11 of 12 Pages

 

EXHIBIT A
JOINT FILING STATEMENT
We, the undersigned, hereby express our agreement that the attached Schedule 13G (or any amendments thereto) relating to the Common Stock of ARCA biopharma, Inc. is filed on behalf of each of us.
         
Dated: February 12, 2010
BOULDER VENTURES IV (ANNEX), L.P.
 		    
By:   BV Partners IV, L.L.C.      
Its: General Partner     
     
By:   /s/ Kyle Lefkoff      
  Kyle Lefkoff, Managing Member     
 
BOULDER VENTURES IV, L.P.
 		    
By:   BV Partners IV, LLC      
Its: General Partner     
     
By:   /s/ Kyle Lefkoff      
  Kyle Lefkoff, Managing Member     
 
BV PARTNERS IV, LLC
 		    
By:   /s/ Kyle Lefkoff      
  Kyle Lefkoff, Managing Member     
     
/s/ Josh E. Fidler      
Josh E. Fidler     
     
/s/ Kyle Lefkoff      
Kyle Lefkoff     
     
/s/ Lawrence M. Macks      
Lawrence M. Macks     
     
/s/ Peter Roshko      
Peter Roshko     

Page 12 of 12 Pages

-----END PRIVACY-ENHANCED MESSAGE-----